Switch theme
Sign up to access all valuation multiples
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
1996
1.3K+
LTM Revenue $3.0B
LTM EBITDA $1.6B
$9.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
United Therapeutics has a last 12-month revenue of $3.0B and a last 12-month EBITDA of $1.6B.
In the most recent fiscal year, United Therapeutics achieved revenue of $2.9B and an EBITDA of $1.7B.
United Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See United Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.3B | $2.9B | XXX | XXX | XXX |
| Gross Profit | $1.8B | $2.1B | XXX | XXX | XXX |
| Gross Margin | 77% | 72% | XXX | XXX | XXX |
| EBITDA | $1.4B | $1.7B | XXX | XXX | XXX |
| EBITDA Margin | 60% | 57% | XXX | XXX | XXX |
| Net Profit | $727M | $985M | XXX | XXX | XXX |
| Net Margin | 31% | 34% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, United Therapeutics's stock price is $284.
United Therapeutics has current market cap of $12.8B, and EV of $9.8B.
See United Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.8B | $12.8B | XXX | XXX | XXX | XXX | $25.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, United Therapeutics has market cap of $12.8B and EV of $9.8B.
United Therapeutics's trades at 3.3x LTM EV/Revenue multiple, and 6.2x LTM EBITDA.
Analysts estimate United Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for United Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.8B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | XXX | XXX |
| P/E | 10.7x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUnited Therapeutics's NTM/LTM revenue growth is 8%
United Therapeutics's revenue per employee for the last fiscal year averaged $2.2M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, United Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate United Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for United Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 57% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 66% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Therapeutics acquired XXX companies to date.
Last acquisition by United Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . United Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was United Therapeutics founded? | United Therapeutics was founded in 1996. |
| Where is United Therapeutics headquartered? | United Therapeutics is headquartered in United States of America. |
| How many employees does United Therapeutics have? | As of today, United Therapeutics has 1.3K+ employees. |
| Who is the CEO of United Therapeutics? | United Therapeutics's CEO is Dr. Martine A. Rothblatt, J.D.,M.B.A.,PhD. |
| Is United Therapeutics publicy listed? | Yes, United Therapeutics is a public company listed on NAS. |
| What is the stock symbol of United Therapeutics? | United Therapeutics trades under UTHR ticker. |
| When did United Therapeutics go public? | United Therapeutics went public in 1999. |
| Who are competitors of United Therapeutics? | Similar companies to United Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of United Therapeutics? | United Therapeutics's current market cap is $12.8B |
| What is the current revenue of United Therapeutics? | United Therapeutics's last 12-month revenue is $3.0B. |
| What is the current EBITDA of United Therapeutics? | United Therapeutics's last 12-month EBITDA is $1.6B. |
| What is the current EV/Revenue multiple of United Therapeutics? | Current revenue multiple of United Therapeutics is 3.3x. |
| What is the current EV/EBITDA multiple of United Therapeutics? | Current EBITDA multiple of United Therapeutics is 6.2x. |
| What is the current revenue growth of United Therapeutics? | United Therapeutics revenue growth between 2023 and 2024 was 24%. |
| Is United Therapeutics profitable? | Yes, United Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
